ProCE Banner Activity

Phase I Study of Gilteritinib Combined With 7+3 Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Updated Results

Slideset Download
Conference Coverage
Combination of the FLT3 inhibitor gilteritinib with standard intensive chemotherapy was active and tolerable as first-line AML therapy.

Released: December 05, 2018

Expiration: December 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology